Log In
Sign Up
Oestriol
Indications
Moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause, female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, palliation in breast cancer (women and men with metastatic disease, prevention of osteoporosis, advanced androgen-dependent carcinoma of the prostate, for palliation only
Dose/Application
For treatment of moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause: the lowest dose that will control symptoms should be selected. Attempts to discontinue or taper medication should be made at 3-month to 6-month intervals. The usual initial dosage is 1 - 2 mg daily. Administration should be cyclic [e.g. 4 weeks on and 1 week off]. For treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure: Treatment is initiated with a dose of 1 - 2 mg daily. For treatment of breast cancer, for palliation only, in appropriately selected women and men with metastatic disease: 10 mg TID for at least three months. For treatment of advanced androgen-dependent carcinoma of the prostate, for palliation only: 1-2 mg TID. The effectiveness of therapy can be judged by phosphatase as well as by symptomatic improvement of the patient determinations. For the prevention of osteoporosis: To be initiated as soon as possible after menopause. 0.5 mg daily administered cyclically [i.e., 23 days on and 5 days off]. The dosage may be adjusted if necessary to control concurrent menopausal symptoms. Discontinuation of estrogen replacement therapy may re-establish the natural rate of bone loss.
Mode of action
Precautions
Contraindications
Side Effects
Pregnancy risk
Special information
Brands containing this Ingredient
Name Form. Strength Pack Price Insert Manufacturer Distributor
Progynova tabs 2mg 20 KES393.00
Drug Index 2.0 is here
Our new update features a more powerful search feature and easier login. Having any issues? Contact us today. Contact Us